WHAT WE DO
Cordis Global Medical Technology Fund is an Australian unit trust of actively-managed global listed companies which make medical devices that provide treatments for critical chronic disease.


Healthcare is a global priority


Critical chronic disease is the highest demand of Healthcare


Medical Devices are one of the fastest growing treatments for chronic disease


Cordis Invests in global listed companies with Proven Medical Devices that treat critical chronic disease
INVESTMENT PROCESS
Integrated Investment Process
The investment team structure for The Fund comprises 3 complementary elements: Each of the 3 groups plays a separate but integrated role in the investment decision making process.
The investment business activities are structured such that the Investment Committee is responsible for setting the investment strategy with significant insights from the Medical Advisory Panel on the trends in healthcare, chronic disease treatments, relevant types of devices, including those accepted as mainstream and growing, those being developed and those being superseded and declining from use. The Portfolio Management team is responsible for the implementation of the investment strategy.


LATEST NEWS
Our News & Updates
RATINGS
The rating contained in this document is issued by SQM Research Pty Ltd ABN 93 122 592 036 AFSL 421913. SQM Research is an investment research firm that undertakes research on investment products exclusively for its wholesale clients, utilising a proprietary review and star rating system. The SQM Research star rating system is of a general nature and does not take into account the particular circumstances or needs of any specific person. The rating may be subject to change at any time. Only licensed financial advisers may use the SQM Research star rating system in determining whether an investment is appropriate to a person’s particular circumstances or needs. You should read the product disclosure statement and consult a licensed financial adviser before making an investment decision in relation to this investment product. SQM Research receives a fee from the Fund Manager for the research and rating of the managed investment scheme.